New kidney anemia drug under Long-Term safety review
NCT ID NCT04899661
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study tracks over 1,000 Japanese patients with renal anemia (low red blood cells due to kidney disease) who are taking molidustat tablets. Researchers are monitoring for serious side effects like blood clots, high blood pressure, and tumors, as well as checking if red blood cell counts improve. The goal is to see how safe and effective the drug is in real-world use over up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Molidustat (a drug taken as a tablet to help the body make more red blood cells)
- What this could lead to
- If successful, this study could confirm that molidustat is a safe and effective long-term treatment for renal anemia, helping patients maintain healthy red blood cell levels.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. There are known risks including blood clots, high blood pressure, and other serious side effects that need careful monitoring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many locations
Multiple Locations, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.